Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 - Seite 2

ESMO Presentation Highlights:

• 17 patients were enrolled and initial data were presented on 16 patients with at least one post baseline scan
• Luvelta demonstrated encouraging preliminary anti-tumor activity in patients with FolRα-expressing endometrial cancer
  • In patients with TPS >25% FolRα expression (n=7):
    • Confirmed partial response (PR) was seen in 29% (2/7)
    • Disease Control Rate (DCR) was 86% (6/7)
  • In patients with TPS ≥1% FolRα expression (n=16):
    • Confirmed PR was seen in 19% (3/16)
    • DCR was 69% (11/16)
• Consistent with previous reported luvelta safety results, the most common adverse event was neutropenia; no new safety signals were observed
  

The Presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.  

*1: Siegel RL, et al. CA Cancer J Clin. 2023;73(1):17–48.
*2: European Cancer Information System (ECIS). https://ecis.jrc.ec.europa.eu. Accessed 11 Oct 2023.
*3: American Cancer Society Cancer Statistics 2023. https://www.cancer.org. Accessed 08 Sep 2023.
*4: Makker V, et al. N Engl J Med. 2022;386(5):437–448.
*5: Despierre E, et al. Gynecol Oncol. 2013;130:192–199.

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.